Eidos Therapeutics
BiotechnologyView the employees at
Eidos Therapeutics-
Ananth Sridhar Corporate Development at BridgeBio
-
San Francisco, California, United States
-
Rising Star
Leonid K. SVP, Clinical Development at Eidos Therapeutics-
San Francisco Bay Area
-
Rising Star
Liara Costa Falco Quality Control / Laboratory Systems Administrator/ Data Integrity-
Macomb, Michigan, United States
-
Top 10%
Overview
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease. Launched in 2016 after years of research supported by Stanford’s SPARK program, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.
-